Key result
Beta-blocker and RAAS inhibitor therapy elicit a positive response in patients with mid-range ejection fraction, similar to the response seen in patients with reduced ejection fraction.
Why the study?
The study evaluated the clinical expedience of isolating patients with heart failure and a mid-range ejection fraction of 40-49% into a separate classification subgroup.
Answers are grounded in this paper and cite their sources.
Heart failure with mid-range ejection fraction is a heterogeneous group that responds to neurohormonal blockade similarly to HFrEF, suggesting that clinical phenotype (e.g., ischemic vs. non-ischemic) should be incorporated into classification.
The article discusses the clinical expedience of isolating into a separate classification subgroup of patients with heart failure and a mid‑range ejection fraction (EF) of 40-49 %. Analysis of studies 2017-2018 focusing on the issue of patients with mid‑range LV EF showed that this subgroup is highly heterogenous and by some clinical and demographic parameters takes an intermediate position between heart failure (HF) patients with reduced (<40 %) and preserved (>50 %) LV EF. However, patients with mid‑range LV EF positively respond to beta‑blocker and RAAS inhibitor therapy, and their response is close to that of patients with reduced LV EF. This is a principal difference between patients with mid‑range and preserved LV EF who generally do not display any beneficial effect of such therapy. One of the major causes for such difference is a dissimilarity of HF etiology and, hence, pathogenesis in patients with reduced and mid‑range LV EF: primarily IHD (so‑called "ischemic" phenotype) in patients with reduced and mid‑range LV EF and non‑cardiac causes ("non‑ischemic" phenotype) in patients with preserved LV EF. Since the nonischemic phenotype is also rather common among patients with mid‑range LV EF a new HF classification should definitely indicate, in addition to LV EF, the clinical phenotype of disease, which is particularly important for patients with mid‑range LV EF of 40-49 %. Further studies should focus on variants of HF clinical phenotypes.
No takes yet. Share an insight, caveat, or question.
Агеев et al. (2018) conducted a review in Heart failure with mid-range ejection fraction. Beta-blocker and RAAS inhibitor therapy was evaluated. Beta-blocker and RAAS inhibitor therapy elicit a positive response in patients with mid-range ejection fraction, similar to the response seen in patients with reduced ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: